Genomic Urine Testing Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Genomic Urine Testing Market By 2029?

The genomic urine testing market has seen rapid expansion recently. This market is projected to increase from $0.9 billion in 2024 to $1.01 billion in 2025, at a compound annual growth rate (CAGR) of 11.9%. The historical growth can be attributed to several factors including the rising prevalence of urologic cancers, the increasing demand for early cancer detection, growing awareness of precision medicine, a higher incidence of genetic disorders, and increasing investments in biomarker discovery.

The market for genomic urine testing is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $1.61 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.4%. This anticipated growth during the forecast period is fueled by factors such as the increasing uptake of liquid biopsy techniques, an intensified focus on personalized medicine, the escalating prevalence of chronic kidney diseases, a heightened emphasis on at-home diagnostic testing solutions, and the expanded application of multi-omics approaches in urine analysis. Key trends identified for the forecast timeframe encompass the development of non-invasive diagnostic methodologies, the creation of highly sensitive test panels, the integration of machine learning pipelines, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

What Are The Key Drivers Of Growth In The Genomic Urine Testing Market?

The escalating burden of chronic kidney disease is projected to fuel the expansion of the genomic urine testing market moving forward. Chronic kidney disease refers to a state where the kidneys are damaged and can no longer effectively filter blood, resulting in a buildup of waste and fluids in the body. The increasing weight of chronic kidney disease is attributed to the rising occurrence of diabetes, as high blood sugar levels harm kidney blood vessels, impairing their ability to filter waste efficiently. Genomic urine testing assists in chronic kidney disease management by enabling the early detection of genetic markers, facilitating timely interventions and personalized treatment plans. It improves patient outcomes by allowing for more accurate monitoring and slowing down disease progression. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the chronic kidney disease (CKD) mortality rates increased from 4.2% in 2021 to 6.2% in 2022. Therefore, the intensifying burden of chronic kidney disease propels the growth of the genomic urine testing market.

What Are The Segment Types Shaping The Genomic Urine Testing Market?

The genomic urine testingmarket covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies

3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring

4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users

Subsegments:

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing

What Key Innovation Trends Are Fueling Advancements In The Genomic Urine Testing Market?

Major companies within the genomic urine testing market are concentrating on developing advanced solutions, including next-generation sequencing, to improve the precision, sensitivity, and early detection capabilities of non-invasive diagnostic tests for a range of diseases. Next-generation sequencing (NGS) represents a sophisticated DNA sequencing technology that facilitates the rapid, accurate, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For example, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, introduced the genomic urine test UroAmp. This test employs next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes linked to bladder cancer, enabling early detection as much as 12 years before clinical symptoms manifest. It provides comprehensive genetic insights to guide diagnosis, inform treatment decisions, and monitor for recurrence, demonstrating superior accuracy compared to traditional methods such as cytology and cystoscopy.

Which Leading Players Are Enhancing Their Genomic Urine Testing Market Presence Worldwide?

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Which Region Is Projected To Lead The Genomic Urine Testing Market During The Forecast Period?

North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Genomic Urine Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2025, By The Business Research Company

Agrigenomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/agrigenomics-global-market-report

Ai In Genomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ai-in-genomics-global-market-report

Blockchain In Genomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blockchain-in-genomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795